MAP2K7 and ovarian carcinoma: Apart from preclinical studies, several clinical trials revealed that MEK inhibitor trametinib, Wee1 inhibitor adavosertib, and CDK4/6 inhibitor ribociclib showed preliminary efficacy in ovarian cancer (159–161).